Xiaolei Zhou
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Xiaolei Zhou has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Mingdong Huang
College of Chemistry, Fuzhou University
3 shared publications Cai Yuan
College of Biological Science and Engineering Fuzhou University 350108 Fuzhou Fujian China P.R
2 shared publicationsGuodong Wang
College of Chemistry, Fuzhou University, Fujian 350116, China
2 shared publicationsLongguang Jiang
College of Chemistry Fuzhou University 350116 Fuzhou Fujian China P.R
2 shared publicationsYang Zhou
College of Chemistry, Fuzhou University, Fujian 350116, China
2 shared publicationsYuhan Mai
College of Chemistry Fuzhou University 350116 Fuzhou Fujian China P.R
2 shared publications
Latest Publications
- Open Access
- 21 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (8) , 4128-4146
ROS-sensitive liposomal co-delivery of photosensitizer, factor Xa inhibitor, and PD-L1 blockade enhances photodynamic immunotherapy
Background: Compared to the lymphodepleting chemotherapy and radiotherapy, photodynamic therapy (PDT) is an oncotherapeutic modality inherently stimulating immune responses by inducing immunogenic cell death (ICD). However, the immunosuppressive tumor microenvironment (TME) frequently attenuates PDT-elicited immune responses, limiting its efficacy in eradicating distant and metastatic tumor cells. Methods: To maximize the immunotherapeutic efficacy of PDT, we developed a photodynamic immunotherapeutic liposomal nanoplatform (PDIT-liposome) integrating components targeting sequential stages of the antitumor immune response: 1) a phthalocyanine photosensitizer to induce ICD, 2) a factor Xa inhibitor (rivaroxaban) to promote T-cell priming, 3) and a program death-ligand 1 inhibitor to augment cytotoxic T lymphocyte (CTL) attack. To enable light-controlled drug release at tumor sites, the liposome was constructed with reactive oxygen species-sensitive phospholipids in response to the PDT effect. Results: PDIT-liposomes were characterized via multiple physicochemical and optical evaluations. Comprehensive in vitro and in vivo investigations confirmed that PDIT-liposomes significantly enhanced antitumor efficacy compared to monotherapies and dual combinations. In a subcutaneous implantation tumor model, PDIT-liposome achieved a 91.7% antitumor rate compared to 21.83% (P-liposome), 46.78% (PD-liposome), and 51.08% (PR-liposome) (p < 0.001). Mechanistic analysis revealed enhanced dendritic cell maturation (8-fold increase in CD11c + cells) and T-cell priming (2.3-fold increase in CD8 + T cells) in tumor-draining lymph nodes (TDLNs), and CTL-mediated cytotoxicity (5.4-fold increase in CD107a + activated CTLs) in TME. Notably, PDIT therapy induced long-term immunological memory, which suppressed 90.68% tumor reoccurrence and metastasis. Conclusion: This study presents a strategy to amplify PDT-elicited immunotherapeutic efficacy by synergizing agents targeting distinct stages of the immune response. It also theoretically validates the synergy of PDT, anticoagulation therapy, and immune checkpoint inhibition in cancer treatment.
- 21 January 2026
- Published by Ivyspring International Publisher in Theranostics
- Vol. 16 (8) , 4128-4146
Open AccessROS-sensitive liposomal co-delivery of photosensitizer, factor Xa inhibitor, and PD-L1 blockade enhances photodynamic immunotherapy
Background: Compared to the lymphodepleting chemotherapy and radiotherapy, photodynamic therapy (PDT) is an oncotherapeutic modality inherently stimulating immune responses by inducing immunogenic cell death (ICD). However, the immunosuppressive tumor microenvironment (TME) frequently attenuates PDT-elicited immune responses, limiting its efficacy in eradicating distant and metastatic tumor cells. Methods: To maximize the immunotherapeutic efficacy of PDT, we developed a photodynamic immunotherapeutic liposomal nanoplatform (PDIT-liposome) integrating components targeting sequential stages of the antitumor immune response: 1) a phthalocyanine photosensitizer to induce ICD, 2) a factor Xa inhibitor (rivaroxaban) to promote T-cell priming, 3) and a program death-ligand 1 inhibitor to augment cytotoxic T lymphocyte (CTL) attack. To enable light-controlled drug release at tumor sites, the liposome was constructed with reactive oxygen species-sensitive phospholipids in response to the PDT effect. Results: PDIT-liposomes were characterized via multiple physicochemical and optical evaluations. Comprehensive in vitro and in vivo investigations confirmed that PDIT-liposomes significantly enhanced antitumor efficacy compared to monotherapies and dual combinations. In a subcutaneous implantation tumor model, PDIT-liposome achieved a 91.7% antitumor rate compared to 21.83% (P-liposome), 46.78% (PD-liposome), and 51.08% (PR-liposome) (p < 0.001). Mechanistic analysis revealed enhanced dendritic cell maturation (8-fold increase in CD11c + cells) and T-cell priming (2.3-fold increase in CD8 + T cells) in tumor-draining lymph nodes (TDLNs), and CTL-mediated cytotoxicity (5.4-fold increase in CD107a + activated CTLs) in TME. Notably, PDIT therapy induced long-term immunological memory, which suppressed 90.68% tumor reoccurrence and metastasis. Conclusion: This study presents a strategy to amplify PDT-elicited immunotherapeutic efficacy by synergizing agents targeting distinct stages of the immune response. It also theoretically validates the synergy of PDT, anticoagulation therapy, and immune checkpoint inhibition in cancer treatment.
- Open Access
Hinokiflavone as a Potential Antitumor Agent: From Pharmacology to Pharmaceutics
Hinokiflavone (HF), a natural C-O-C-linked biflavonoid originally isolated from Chamaecyparis obtusa, is a promising multifunctional antitumor agent. Despite challenges posed by multidrug resistance and tumor heterogeneity, HF demonstrates notable therapeutic potential through a multifaceted pharmacological profile. HF exerts broad-spectrum anticancer effects by targeting multiple oncogenic pathways, including the MDM2-p53 axis, MAPK/JNK/NF-κB signaling, ROS/JNK-mediated apoptosis, and Bcl-2/Bax-regulated mitochondrial pathways. These actions are further complemented by inhibition of cell proliferation through cell cycle arrest and suppression of metastasis via downregulation of matrix metalloproteinases and reversal of epithelial–mesenchymal transition. Additionally, HF displays antioxidant, anti-inflammatory, and antimicrobial activities, enhancing treatment efficacy. However, its clinical translation remains limited by poor aqueous solubility, low oral bioavailability, and incomplete pharmacokinetic characterization. Recent advances in nanotechnology-based formulation strategies, such as polymeric micelles and metal–organic frameworks, have enhanced HF’s bioavailability and in vivo antitumor efficacy. This review comprehensively delineates HF’s molecular mechanisms of anticancer action, evaluates its pharmacokinetics and bioformulation developments, and highlights challenges and prospects for clinical application. Integration of tumor microenvironment-responsive delivery systems with synergistic therapeutic strategies is essential to fully realize HF’s therapeutic potential, positioning it as a valuable scaffold for novel anticancer drug development.
Open AccessHinokiflavone as a Potential Antitumor Agent: From Pharmacology to Pharmaceutics
Hinokiflavone (HF), a natural C-O-C-linked biflavonoid originally isolated from Chamaecyparis obtusa, is a promising multifunctional antitumor agent. Despite challenges posed by multidrug resistance and tumor heterogeneity, HF demonstrates notable therapeutic potential through a multifaceted pharmacological profile. HF exerts broad-spectrum anticancer effects by targeting multiple oncogenic pathways, including the MDM2-p53 axis, MAPK/JNK/NF-κB signaling, ROS/JNK-mediated apoptosis, and Bcl-2/Bax-regulated mitochondrial pathways. These actions are further complemented by inhibition of cell proliferation through cell cycle arrest and suppression of metastasis via downregulation of matrix metalloproteinases and reversal of epithelial–mesenchymal transition. Additionally, HF displays antioxidant, anti-inflammatory, and antimicrobial activities, enhancing treatment efficacy. However, its clinical translation remains limited by poor aqueous solubility, low oral bioavailability, and incomplete pharmacokinetic characterization. Recent advances in nanotechnology-based formulation strategies, such as polymeric micelles and metal–organic frameworks, have enhanced HF’s bioavailability and in vivo antitumor efficacy. This review comprehensively delineates HF’s molecular mechanisms of anticancer action, evaluates its pharmacokinetics and bioformulation developments, and highlights challenges and prospects for clinical application. Integration of tumor microenvironment-responsive delivery systems with synergistic therapeutic strategies is essential to fully realize HF’s therapeutic potential, positioning it as a valuable scaffold for novel anticancer drug development.
- Open Access
- 19 September 2025
- Published by Scilight Press Pty Ltd in Health and Metabolism
- Vol. 2 (4)
Targeting Inflammatory Cytokines in Autoimmune Diseases: Mechanisms and Therapeutic Advances with Antibody-Based Therapies
Autoimmune diseases occur due to dysregulated immune responses against self-antigens, marked by chronic inflammation caused by pathogenic cytokine networks. Key inflammatory mediators, such as TNF-α, IL-6, IL-17, IL-23, and type I/II interferons, promote disease progression by activating autoreactive lymphocytes, recruiting immune cells, and causing ongoing tissue damage. The development of therapeutic antibodies targeting these cytokines has transformed treatment approaches, providing targeted immunomodulation while reducing systemic immunosuppression. Clinically approved biologics, including TNF inhibitors (Adalimumab, Infliximab), IL-6R blockers (Tocilizumab), and IL-17/IL-23 pathway antagonists (Secukinumab, Ustekinumab), show strong efficacy in various autoimmune conditions like rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. Emerging strategies, such as bispecific antibodies and AI-optimized designs, further enhance therapeutic precision by targeting multiple inflammatory pathways or refining antibody functions simultaneously. This review highlights the pivotal role of inflammatory cytokines in autoimmune pathogenesis and assesses the clinical impact of cytokine-targeted biologics, emphasizing their potential for achieving disease modification and long-term remission. Future advancements in personalized immunomodulation are expected to improve therapeutic outcomes for refractory autoimmune diseases.
- 19 September 2025
- Published by Scilight Press Pty Ltd in Health and Metabolism
- Vol. 2 (4)
Open AccessTargeting Inflammatory Cytokines in Autoimmune Diseases: Mechanisms and Therapeutic Advances with Antibody-Based Therapies
Autoimmune diseases occur due to dysregulated immune responses against self-antigens, marked by chronic inflammation caused by pathogenic cytokine networks. Key inflammatory mediators, such as TNF-α, IL-6, IL-17, IL-23, and type I/II interferons, promote disease progression by activating autoreactive lymphocytes, recruiting immune cells, and causing ongoing tissue damage. The development of therapeutic antibodies targeting these cytokines has transformed treatment approaches, providing targeted immunomodulation while reducing systemic immunosuppression. Clinically approved biologics, including TNF inhibitors (Adalimumab, Infliximab), IL-6R blockers (Tocilizumab), and IL-17/IL-23 pathway antagonists (Secukinumab, Ustekinumab), show strong efficacy in various autoimmune conditions like rheumatoid arthritis, systemic lupus erythematosus, and psoriasis. Emerging strategies, such as bispecific antibodies and AI-optimized designs, further enhance therapeutic precision by targeting multiple inflammatory pathways or refining antibody functions simultaneously. This review highlights the pivotal role of inflammatory cytokines in autoimmune pathogenesis and assesses the clinical impact of cytokine-targeted biologics, emphasizing their potential for achieving disease modification and long-term remission. Future advancements in personalized immunomodulation are expected to improve therapeutic outcomes for refractory autoimmune diseases.
- 11 June 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 163, 108678
Treatment of diabetic infection wounds using novel fluoroborane dipyrrole-coated transparent patch
- 11 June 2025
- Published by Elsevier in Bioorganic Chemistry
- Vol. 163, 108678
Treatment of diabetic infection wounds using novel fluoroborane dipyrrole-coated transparent patch
- 30 October 2024
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 261, 113045
Lysosome-localization and tumor-targeting of novel photosensitizers enhance the ablation of cancer
- 30 October 2024
- Published by Elsevier in Journal of Photochemistry and Photobiology B: Biology
- Vol. 261, 113045
Lysosome-localization and tumor-targeting of novel photosensitizers enhance the ablation of cancer